HSPG2 and hepatocellular carcinoma: Nevertheless, Hsiang and colleagues26 observed that statin use was still associated with a reduced risk of hepatocellular carcinoma after eliminating this bias with the landmark analysis method, indicating that immortal time bias did not play a major role in the association between statin use and PLC risk.